Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.57 |
| ▸ | BCHE | P06276 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | ANPEP | P15144 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10533348 | 1.00 | DNM1 (0.57) | DNM1BCHEALDH1A1ANPEPCYP1A2 | |
| SCHEMBL893963 | 0.90 | BCHE (0.63) | DNM1BCHEALDH1A1ANPEPCYP1A2 | |
| SCHEMBL9168696 | 0.86 | DNM1 (0.49) | DNM1BCHEALDH1A1ANPEPCYP1A2 | |
| SCHEMBL14015727 | 0.84 | DNM1 (0.57) | DNM1BCHEALDH1A1ANPEPCYP1A2 | |
| SCHEMBL2919287 | 0.82 | DNM1 (0.55) | DNM1BCHEALDH1A1ANPEPCYP1A2 | |
| SCHEMBL19122419 | 0.82 | DNM1 (0.55) | DNM1BCHEALDH1A1ANPEPCYP1A2 | |
| SCHEMBL2305792 | 0.82 | DNM1 (0.55) | DNM1BCHEALDH1A1ANPEPCYP1A2 | |
| SCHEMBL2840755 | 0.82 | DNM1 (0.55) | DNM1BCHEALDH1A1ANPEPCYP1A2 | |
| SCHEMBL3029456 | 0.82 | DNM1 (0.59) | DNM1BCHEALDH1A1ANPEPCYP1A2 | |
| SCHEMBL14532283 | 0.82 | DNM1 (0.55) | DNM1BCHEALDH1A1ANPEPCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118324707-A | Synthesis method of (S) -6-hydroxymethyl-morpholin-3-one | 西安宇特邦医药科技有限公司 | 2024-07-12 | — | — | CN | claimed |
| EP-0863875-B1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | HOFFMANN LA ROCHE (CH) | 2003-06-04 | — | — | EP | claimed |
| EP-0863875-A1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | F. HOFFMANN-LA ROCHE AG (CH) | 1998-09-16 | — | — | EP | claimed |
| WO-1997009311-A1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | F. HOFFMANN-LA ROCHE AG (CH) | 1997-03-13 | — | — | WO | claimed |
| CN-117777048-B | Preparation method of chiral 2-hydroxymethylmorpholine-4-carboxylic acid tert-butyl ester | 上海科利生物医药有限公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-118420543-A | Tumor inhibitor targeting EP300 mutation and application thereof | 上海美得诺瓦生物医药科技有限公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-118324707-A | Synthesis method of (S) -6-hydroxymethyl-morpholin-3-one | 西安宇特邦医药科技有限公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-117777048-A | Preparation method of chiral 2-hydroxymethylmorpholine-4-carboxylic acid tert-butyl ester | 上海科利生物医药有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-10808246-B2 | Oligonucleotide-ligand conjugates and process for their preparation | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| CN-103525435-B | Crystal aligning agent, the manufacture method of liquid crystal display cells, liquid crystal orienting film, liquid crystal display cells and polymer | JSR株式会社 | 2016-09-14 | — | — | CN | disclosed |
| CN-103666487-B | Crystal aligning agent, liquid crystal orienting film and liquid crystal display cells | JSR株式会社 | 2016-08-24 | — | — | CN | disclosed |
| CN-103509563-B | Light orientation crystal aligning agent, liquid crystal orienting film and manufacture method, liquid crystal display cells, compound and polymer | JSR株式会社 | 2016-08-10 | — | — | CN | disclosed |
| US-4652563-A | PYRIDAZINONES SUBSTITUTED WITH CYCLOPROPYLMETHOXYETHYL GROUP | SMITH KLINE & FRENCH LABORATORIES LTD. (GB) | 1987-03-24 | — | — | US | disclosed |
| WO-1986006368-A1 | STEREOSELECTIVE PROCESS AND CHIRAL INTERMEDIATES FOR ARYLOXYDROPANOLAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1986-11-06 | — | — | WO | disclosed |
| EP-0168921-A2 | Chemical compounds | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1986-01-22 | — | — | EP | disclosed |
| US-4410530-A | CARDIO-SELECTIVE B-RECEPTOR BLOCKING AGENTS AND STIMULANTS | CIBA-GEIGY CORPORATION (US) | 1983-10-18 | — | — | US | disclosed |
| US-4195090-A | ADRENERGIC BLOCKING AGENTS | CIBA-GEIGY CORPORATION (US) | 1980-03-25 | — | — | US | disclosed |
| US-4139623-A | HYPOTENSIVE AGENTS | C-G CORP. (US) | 1979-02-13 | — | — | US | disclosed |
| US-4115575-A | CARDIOVASCULAR DISORDERS | CIBA-GEIGY CORPORATION (US) | 1978-09-19 | — | — | US | disclosed |
| US-4027027-A | BETA-RECEPTOR-BLOCKERS, HYPOTENSIVES AND VALODILATORS; FOR TREATING ARRYTHMIAS AND ANGINA PECTORIS | CIBA-GEIGY CORPORATION (US) | 1977-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10808246-B2 | Oligonucleotide-ligand conjugates and process for their preparation | RTCB, IGF2BP2, SNRPE | DNM1 1874/4885BCHE 4801/4885ALDH1A1 1611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.